Isoniazid pharmacokinetics in children treated for respiratory tuberculosis

Archives of Disease in Childhood

Volumn 90, Issue 6, 2005, Pages 614-618

  Schaaf, H S ^a   Parkin, D P ^b   Seifart, H I ^b   Werely, C J ^b   Hesseling, P B ^a   Van Helden, P D ^b   Maritz, J S ^c   Donald, P R ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ISONIAZID;

ACETYLATOR PHENOTYPE; ADOLESCENT; ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; ETHNOLOGY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INFANT; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ADOLESCENT; ADULT; AGING; ANALYSIS OF VARIANCE; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; ARYLAMINE N-ACETYLTRANSFERASE; CHILD; CHILD, PRESCHOOL; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INFANT; INFANT, NEWBORN; ISONIAZID; TUBERCULOSIS, PULMONARY;

EID: 20344403751     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2004.052175     Document Type: Article

References (35)

1. Fox HH. The chemical approach to the control of tuberculosis. Science 1952;116:129-34.
2. American Academy of Pediatrics. Tuberculosis. In: Pickering LK, ed. Red Book: 2003 Report of the Committee on Infectious Diseases, 26th edn. Elk Grove Village, IL: American Academy of Pediatrics, 2003:642-60.
3. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49:1-51.
4. Donald PR, Sirgel FA, Botha FJ, et al. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med 1997;156:895-900.
5. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000;4:796-806.
6. Crowle AJ, Sbarbaro JA, May MH. Effects of isoniazid and cefaramide against virulent tubercle bacilli in cultured human macrophages. Tubercle 1988;69:15-25.
7. McCune RM, Feldman FM, Lambert HP, et al. Microbial persistence 1. The capacity of tubercle bacilli to survive in mouse tissues. J Exp Med 1966;123:445-68.
8. Weber WW, Hein HW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet 1979;4:401-22.
9. Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. BMJ 1960;2:485-91.
10. Sunahara S, Urano M, Agawa M. Genetic and geographical studies on isoniazid inactrvation. Science 1961;134:1530-1.
11. Parkin DP, Vandenplas S, Botha FJH, et al. Trimodality of isontazid elimination. Am J Respir Crit Care Med 1997;155:1717-22.
12. Pariente-Khayat A, Rey E, Gendrel D, et al. Isoniazid acetylation metabolic ratio during maturation in children. Clin Pharmacol Ther 1997;62:377-83.
13. Rey E, Gendrel D, Treyluyer JM, et al. Isoniazid pharmacokinetics in children according to acetylator phenotype. Fund Clin Pharmacol 2001;15:355-9.
14. Seth V, Beotra A. Antituberculosis drugs. II: Clinical pharmacokinetics in Indian children. In: Seth V, eds. Essentials of tuberculosis in children. Delhi, India: Jaypee Brothers Medical Publishers, 1997:291-303.
15. Seifart HI, Gent WL, Parkin DP, et al. High-performance liquid chromatographic determination of isoniazid, acetyllsoniazid and hydrazine in biological fluids. J Chromatograph B 1995;674:269-75.
16. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
17. Vatsis KP, Weber WW, Bell DA, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5:1-17.
18. Hamajima NT, Saito T, Matsuo K, et al. Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping. Jpn J Cancer Res 2000;91:865-8.
19. Bassam BJ, Caetano-Anollés G, Gresshoff PM. Fast and sensitive silver staining of DNA in polyacrylamide gels. Anal Biochem 1991;196:80-3.
20. Weber WW. Determination of the human acetylator status. In: The acetylator genes and drug response. New York: Oxford University Press, 1987:151-73.
21. Maritz JS, Donald PR, Schaaf HS, et al. The association of age and the elimination of isoniazid: an example of median regression with heteroscedasticity. S Afr Statist J 2003;37:191-202.
22. Houin G, Tillemenl JP. Consequences thérapeutiques de la mesure de l'indice d'inactivation de l'isoniazide au cours du traitement antituberculeux. Therapie 1980;35:597-605.
23. Advenier C, Saint-Aubin A, Scheinmann P, et al. Pharmacocinétique de l'isoniazide chez l'enfant. Rev Fr Mal Respir 1981;9:365-74.
24. Bouveret JP, Hanoteau J, Gerbeaux J, et al. Variations de l'indice d'inactivation de l'isoniazide au cours des traitements antituberculeux chez l'enfant. Archiv Fr Pediatr 1983;40:615-19.
25. Lupasco I, Algeorge G, Ghiu-Cimpeanu V. Taux d'isoniazide actif dans le serum des enfants tuberculeux. Pneumon Coeur 1965;21:1105-14.
26. Peloquin CA. Therapeutic drug monitoring: principles and application in mycobacterial infections. Drug Ther 1992;22:31-6.
27. Vivien JN, Thibier R, Grosset J, et al. Resultats précoces de l'isoniazido-thérapie en fonction du taux d'isoniazide actif dans le sérum. Rev Tuberc 1958;22:208-22.
28. International Union Against Tuberculosis and Lung Disease. Tuberculosis in children: guidelines for diagnosis, prevention and treatment. Bull Int Union Tuberc Lung Dis 1991;66:61-7.
29. Enarson DA, Rieder HL, Arnodottir T, et al. Management of tuberculosis: a guide for low income countries, 5th edn. Paris: IUATLD, 2000.
30. World Health Organisation. Standardized treatment regimen. In: Treatment of tuberculosis: guidelines for national programmes. WHO/CDS/ TB2003.313. Geneva: WHO, 2003:27-38.
31. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1988. Thorax 1998;53:536-48.
32. Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997;127:289-93.
33. Iseman MD, Madsen LA. Chronic tuberculous empyema with bronchopleural fistula resulting in treatment failure and progressive drug resistance. Chest 1991;100:124-7.
34. Elliolt AM, Berning SE, Iseman MD, et al. Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Tubercle Lung Dis 1995;76:463-7.
35. Schoeman JF, Morkel A, Seifart HI, et al. Massive posterior fossa tuberculous abscess developing in a young child treated for miliary tuberculosis. Possible role of very rapid acetylation of isoniazid. Pediatr Neurosurg 1998;29:64-8.